This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Semler Scientific Inc. (SMLR) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of -21.54% and -10.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Hologic (HOLX) Adds New Products to Omni Hysteroscopy Offering
by Zacks Equity Research
Hologic (HOLX) expands Omni suite in EMEA with the new Omni 30 degree hysteroscope, Omni Lok cervical seal and Omni 5 French seal products.
Illumina (ILMN) Oncology Growth Aids Amid GRAIL Merger Hurdle
by Zacks Equity Research
Illumina (ILMN) is making progress outside the United States to ensure all expecting families have access to NIPT.
Thermo Fisher (TMO) Launches Kit for Safer Sample Collection
by Zacks Equity Research
Thermo Fisher (TMO) launches SpeciMAX Stabilized Saliva Collection Kit that can support global efforts toward SARS-CoV-2 research by ensuring safer saliva collection.
Globus Medical (GMED) Progresses With ExcelsiusGPS in DBS
by Zacks Equity Research
According to Globus Medica (GMED), the clinical superiority of ExcelsiusGPS continues to be recognized by surgeons.
Orthofix (OFIX) Reaches Milestone for M6-C Disc Implants
by Zacks Equity Research
Orthofix (OFIX) reveals that more than 60,000 M6-C artificial cervical discs have been implanted worldwide.
Semler Scientific Inc. (SMLR) Surges 11.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Semler Scientific Inc. (SMLR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
NEOGEN (NEOG) Igenity Branded Calves Score Highest US Sales
by Zacks Equity Research
NEOGEN's (NEOG) Igenity-tested calves earn an average premium of over $59 in the summer selling season.
Thermo Fisher's (TMO) Delta Q IRMS to Back Sustainable Science
by Zacks Equity Research
Thermo Fisher (TMO) has introduced the new Delta Q IRMS under the IsoFootprint campaign to support sustainable science by eliminating carbon dioxide emission.
Thermo Fisher (TMO) Introduces New Automated Enzyme Analyzers
by Zacks Equity Research
The two new Gallery Enzyme Master systems by Thermo Fisher (TMO) offer enhanced reliable enzyme analysis across several enterprises.
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for EXKIVITY
by Zacks Equity Research
Thermo Fisher (TMO) gains FDA pre-market approval for Oncomine Dx as companion diagnostic for Takeda's EXKIVITY.
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval From MHLW
by Zacks Equity Research
Thermo Fisher's (TMO) Oncomine Dx Target Test has been approved by MHLW as a companion diagnostic for Eli Lilly and Company's selpercatinib.
Here's Why You Should Add STERIS (STE) to Your Portfolio Now
by Zacks Equity Research
STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.
Zimmer Biomet (ZBH) Hurt by EMEA's Slow Recovery Amid Pandemic
by Zacks Equity Research
Zimmer Biomet's (ZBH) leveraged capital structure is an added concern.
Thermo Fisher (TMO) Gains Government Contract for Pipette Tip
by Zacks Equity Research
Thermo Fisher (TMO) will co-invest with the U.S. government to build a new manufacturing center for pipette tips in North Carolina.
Here's Why You Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for TIBSOVO
by Zacks Equity Research
Thermo Fisher (TMO) receives FDA go-ahead for the Oncomine Dx Target Test as a CDx for Servier's ivosidenib tablets, TIBSOVO.
SmileDirectClub (SDC) Reels Under Rising Costs, Debt Woes
by Zacks Equity Research
SmileDirectClub (SDC) sees net operating cash outflow in the second quarter.
Teleflex (TFX) Rides on UroLift Growth, Hurt by Pandemic Woes
by Zacks Equity Research
Teleflex (TFX) has decided to increase its investment in 2021 and run a national campaign for the full year.
Globus Medical (GMED) Gets FDA Nod for Excelsius3D
by Zacks Equity Research
The receipt of FDA's 510(k) clearance for Globus Medical's (GMED) Excelsius3D is expected to expand the company's presence in the intraoperative imaging system space.
Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev
by Zacks Equity Research
Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.
Amedisys (AMED) Suffers From Low Occupancy Amid Pandemic
by Zacks Equity Research
The prolonged and lingering impact of COVID-19 on Amedisys (AMED) Hospice business has hampered its ability to grow at the earlier-projected rates.
Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the four reported business segments is driving the top line for Thermo Fisher (TMO).
Semler Scientific Inc. (SMLR) Q2 Earnings Top Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 36.07% and -1.51%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Semler Scientific Inc. (SMLR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Semler Scientific Inc. (SMLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.